A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma

Twice‐weekly carfilzomib with lenalidomide‐dexamethasone (Rd) is an effective regimen for newly diagnosed multiple myeloma (NDMM). Here we evaluated once‐weekly carfilzomib with Rd (once‐weekly KRd) in NDMM patients. The NDMM patients were enrolled regardless of transplant eligibility. Patients rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsina, Melissa, Landgren, Ola, Raje, Noopur, Niesvizky, Ruben, Bensinger, William I., Berdeja, Jesus G., Kovacsovics, Tibor, Vesole, David H., Fang, Belle, Kimball, Amy S., Siegel, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898514/
https://www.ncbi.nlm.nih.gov/pubmed/33125764
http://dx.doi.org/10.1002/ajh.26041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898514/
https://www.ncbi.nlm.nih.gov/pubmed/33125764
http://dx.doi.org/10.1002/ajh.26041

Ejemplares similares